ArticleBMC molecular biology2010
Targeting of highly conserved Dengue virus sequences with anti-Dengue virus trans-splicing group I introns.
Article in BMC molecular biology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 31 citations in OpenAlex.
- Design and testing of Hepatitis Delta Ribozymes for suppression of Chikungunya virus infection in cell cultures.Medical research archives · 2024Article
- Oligonucleotide-Based Approaches to Inhibit Dengue Virus Replication.Molecules (Basel, Switzerland) · 2021Review
- Therapeutic applications of trans-splicing.British medical bulletin · 2020Article
- CRISPR-Cas12a based internal negative control for nonspecific products of exponential rolling circle amplification.Nucleic acids research · 2020Article
- Advances in engineered trans-acting regulatory RNAs and their application in bacterial genome engineering.Journal of industrial microbiology & biotechnology · 2019Review
- Review
- Design and Experimental Evolution of trans-Splicing Group I Intron Ribozymes.Molecules (Basel, Switzerland) · 2017Review
- Trans-splicing group I intron targeting hepatitis C virus IRES mediates cell death upon viral infection in Huh7.5 cells.Virology · 2015Article
- Disruption of dengue virus transmission by mosquitoes.Current opinion in insect science · 2015Article
- Article
- Effective suppression of dengue virus using a novel group-I intron that induces apoptotic cell death upon infection through conditional expression of the Bax C-terminal domain.Virology journal · 2014Article
- Inhibition of Dengue virus 2 replication by artificial micrornas targeting the conserved regions.Nucleic acid therapeutics · 2013Article
- A novel dengue virus detection method that couples DNAzyme and gold nanoparticle approaches.Virology journal · 2013Article
- Computational prediction of efficient splice sites for trans-splicing ribozymes.RNA (New York, N.Y.) · 2012Article
- Inhibition of dengue virus infections in cell cultures and in AG129 mice by a small interfering RNA targeting a highly conserved sequence.Journal of virology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundDengue viruses (DENV) are one of the most important viral diseases in the world with approximately 100 million infections and 200,000 deaths each year. The current lack of an approved tetravalent vaccine and ineffective insecticide control measures warrant a search for alternatives to effectively combat DENV. The trans-splicing variant of the Tetrahymena thermophila group I intron catalytic RNA, or ribozyme, is a powerful tool for post-transcriptional RNA modification. The nature of the ribozyme and the predictability with which it can be directed makes it a powerful tool for modifying RNA in nearly any cell type without the need for genome-altering gene therapy techniques or dependence on native cofactors.
resultsSeveral anti-DENV Group I trans-splicing introns (αDENV-GrpIs) were designed and tested for their ability to target DENV-2 NGC genomes in situ. We have successfully targeted two different uracil bases on the positive sense genomic strand within the highly conserved 5'-3' cyclization sequence (CS) region common to all serotypes of DENV with our αDENV-GrpIs. Our ribozymes have demonstrated ability to specifically trans-splice a new RNA sequence downstream of the targeted site in vitro and in transfected insect cells as analyzed by firefly luciferase and RT-PCR assays. The effectiveness of these αDENV-GrpIs to target infecting DENV genomes is also validated in transfected or transformed Aedes mosquito cell lines upon infection with unattenuated DENV-2 NGC.
conclusionsAnalysis shows that our αDENV-GrpIs have the ability to effectively trans-splice the DENV genome in situ. Notably, these results show that the αDENV-GrpI 9v1, designed to be active against all forms of Dengue virus, effectively targeted the DENV-2 NGC genome in a sequence specific manner. These novel αDENV-GrpI introns provide a striking alternative to other RNA based approaches for the transgenic suppression of DENV in transformed mosquito cells and tissues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.